Dr. Vivek K. Narayan, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 249
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Virginia School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD447525 -
Internal Medicine Physician
PA license MT197340
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Chester County Hospital West Chester, PA
- Lancaster General Hospital Lancaster, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 249
- Services billed
- 1,003
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 271 | 143 |
| Established patient office or other outpatient visit, 30-39 minutes | 214 | 125 |
| New patient office or other outpatient visit, 60-74 minutes | 48 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xtandi (enzalutamide) | 108 |
| Prednisone Other prescribers in Philadelphia, PA | 49 |
| Abiraterone Acetate | 45 |
| Cabometyx (cabozantinib s-malate) | 39 |
| Lenvima (lenvatinib mesylate) | 27 |
| Bicalutamide | 26 |
| Nubeqa (darolutamide) | 23 |
| Orgovyx (relugolix) | 16 |
| Welireg (belzutifan) | 15 |
| Levothyroxine Sodium Other prescribers in Philadelphia, PA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 22 payments worth $24,373 in total to this clinician.
| Sumitomo Pharma America, Inc. | $6,975 |
|---|---|
| Pfizer Inc. | $6,640 |
| Exelixis Inc. | $3,531 |
| Bayer HealthCare Pharmaceuticals Inc. | $3,456 |
| Astellas Pharma Global Development | $2,100 |
| Merck Sharp & Dohme LLC | $1,590 |
| AstraZeneca Pharmaceuticals LP | $64.06 |
| Caris Mpi, Inc. | $17.65 |
| Consulting Fee | $19,161 |
|---|---|
| Honoraria | $2,310 |
| Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Food and Beverage | $742 |
| Travel and Lodging | $656 |
| Education | $3.78 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $5,922 |
| Pfizer Inc. Jan 8, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $5,040 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Kerendia · Cardio-Renal | $3,456 |
| Exelixis Inc. Mar 27, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,310 |
| Astellas Pharma Global Development Dec 12, 2025 | Consulting Fee Xtandi · Oncology | $2,100 |
| Pfizer Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $846 |
| Exelixis Inc. Mar 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Dallas, TX · in-kind | $551 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Consulting Fee WELIREG · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $530 |
| Merck Sharp & Dohme LLC Mar 12, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $530 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma Global Development Dec 12, 2025 | Consulting Fee Xtandi · Oncology | $2,100 |
| Pfizer Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $5,922 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $846 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $207 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Kerendia · Cardio-Renal | $3,456 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $530 |
| Pfizer Inc. Jul 18, 2025 | Education TALZENNA; XTANDI · ONCOLOGY · in-kind | $3.78 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Consulting Fee WELIREG · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $530 |
| Exelixis Inc. Mar 27, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,310 |
| Exelixis Inc. Mar 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Dallas, TX · in-kind | $551 |
| Exelixis Inc. Mar 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Dallas, TX · in-kind | $70.00 |
| Exelixis Inc. Mar 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Dallas, TX | $35.00 |
| Merck Sharp & Dohme LLC Mar 12, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $530 |
| Pfizer Inc. Jan 8, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $5,040 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $2,562,491 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Merck Sharp & Dohme LLC - Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
Merck Sharp & Dohme LLC - STUDY NAME#Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab ,- Lenvatinib for High Risk Renal Cell Carcinoma
Merck Sharp & Dohme LLC - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05125016 - Avelumab master protocol an openlabel continuation study for participants continuing from pfizersponsored avelumab clinical studies
Pfizer Inc. - BNT211
BioNTech SE - A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
Merck Sharp & Dohme LLC - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer
E.r. Squibb & Sons, L.l.c. - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.